MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
Hospital Universitario Reina Sofia
Córdoba, EspañaHospital Universitario Reina Sofia -ko ikertzaileekin lankidetzan egindako argitalpenak (13)
2023
-
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400
2021
2020
-
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213
-
Serum phospholipids fatty acids and breast cancer risk by pathological subtype
Nutrients, Vol. 12, Núm. 10, pp. 1-18
2017
-
A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse
Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044
-
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21930-21937
2015
-
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer
Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137
-
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): A randomized, noninferiority phase II trialwith a pharmacogenetic analysis
Oncologist, Vol. 20, Núm. 2, pp. 111-112
2011
-
Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer
Breast Cancer Research and Treatment, Vol. 125, Núm. 1, pp. 273-278
2009
-
Prognostic and predictive factors and genetic analysis of early breast cancer
Clinical and Translational Oncology
2008
-
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007
Clinical and Translational Oncology, Vol. 10, Núm. 9, pp. 552-559
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814